title: Angiogenic imbalance and plasma lipid alterations in women with preeclampsia from a developing country.
abstract: BACKGROUND
  An imbalance between anti-angiogenic factors (e.g. soluble vascular endothelial growth factor receptor-1 (s-FLT1) and soluble endoglin (s-Eng)) and pro-angiogenic factors (e.g. placental growth factor (PlGF)) as well as increased oxidized low-density lipoprotein (ox-LDL) concentrations have been associated with preeclampsia (PE). Risk factors associated with the development of PE, however, are known to be different between developed and developing countries. The aim of the study was to determine the levels of s-FLT1, s-Eng, PIGF, and ox-LDL in women with PE from a developing country.
  
  
  METHODS
  A multi-center case-control study was conducted. One hundred and forty three women with PE were matched by age and parity with 143 healthy pregnant women without cardiovascular or endocrine diseases. Before delivery, blood samples were taken and serum was stored until analysis.
  
  
  RESULTS
  Women with PE had lower concentrations of PIGF (p<0.0001) and higher concentrations of s-Eng (p=0.001) than healthy pregnant women. There were no differences between the groups regarding ox-LDL or s-FLT1. Women with early onset PE had higher s-FLT1 concentrations (p=0.0004) and lower PIGF concentrations (p<0.0001) than their healthy pregnant controls. Women with late onset PE had higher concentrations of s-Eng (p=0.005). Women with severe PE had higher concentrations of s-Eng (p=0.0008) and ox-LDL (p=0.01), and lower concentrations of PIGF (p<0.0001).
  
  
  CONCLUSIONS
  Women with PE from a developing country demonstrated an angiogenic imbalance and an increased rate of LDL oxidation. Findings from this study support the theory that PE is a multifactorial disease, and understanding differences in these subpopulations may provide a better target to approach future therapies.
authors.affiliation: Department of Gynecology and Obstetrics, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: L M
authors.initials: LM
authors.lastname: Reyes
authors.forename: R G
authors.initials: RG
authors.lastname: García
authors.forename: S L
authors.initials: SL
authors.lastname: Ruiz
authors.forename: D
authors.initials: D
authors.lastname: Broadhurst
authors.forename: G
authors.initials: G
authors.lastname: Aroca
authors.forename: S T
authors.initials: ST
authors.lastname: Davidge
authors.forename: P
authors.initials: P
authors.lastname: López-Jaramillo
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003105:Colombia; D003906:Developing Countries; D000071063:Endoglin; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D018919:Neovascularization, Physiologic / Q000502:physiology*; D000072483:Placenta Growth Factor; D011225:Pre-Eclampsia / Q000097:blood*; D011247:Pregnancy; D011248:Pregnancy Complications; D011257:Pregnancy Proteins / Q000097:blood*; D011956:Receptors, Cell Surface / Q000097:blood*; D012307:Risk Factors; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood*; D055815:Young Adult
chemical_list: D015703:Antigens, CD; D015415:Biomarkers; C064206:ENG protein, human; D000071063:Endoglin; D008077:Lipoproteins, LDL; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D011956:Receptors, Cell Surface; C099252:oxidized low density lipoprotein; D000072483:Placenta Growth Factor; D040281:Vascular Endothelial Growth Factor Receptor-1